Aytu BioPharma Exceeds Expectations with Strong ADHD Portfolio Performance and Positive Q1 2026 Earnings Call Highlights

Aytu BioPharma reported Q1 2026 net revenue of $13.9 million, exceeding expectations due to strong ADHD portfolio performance. The ADHD portfolio saw a 10% increase in net revenue compared to the previous year, excluding a one-time rebate benefit. The company has a strong cash position with $32.6 million in cash and cash equivalents. However, net revenue for the quarter decreased from $16.6 million in the prior year, and gross margin decreased to 66% from 72% in the previous year.